Can math make thyroid hormone therapy more precise?

NCT ID NCT07752277

First seen Aug 07, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This trial tests a new way to personalize the dose of levothyroxine, a thyroid hormone medication, for people who have had surgery for thyroid cancer. Using mathematical and statistical models, the approach aims to predict the best dose for each individual, potentially reducing side effects and improving treatment outcomes. The study includes adults aged 18-65 with advanced or metastatic thyroid cancer who are about to undergo total or near-total thyroidectomy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
levothyroxine sodium tablets (Euthyrox)
What this could lead to
If successful, this could lead to a personalized dosing strategy that helps thyroid cancer patients achieve better hormone balance with fewer side effects after surgery.
What could go wrong
The trial is relatively small and early, and the mathematical model may not work for everyone. Individual responses to the drug can vary, so the approach might not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID AND OTHER ENDOCRINE GLAND CARCINOMA IN SITU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.